Document:

Named Executive Officers Salary and Bonus Arrangements for 2008

 Exhibit 10.7 
 Named Executive Officers Salary and Bonus Arrangements for 2009 
 Base Salaries

 The base salaries for 2009 for the executive officers (the “named executive officers”) of First PacTrust
Bancorp, Inc. (the “Company”) and Pacific Trust Bank who will be named in the compensation table that will appear in the Company’s upcoming 2009 annual meeting proxy statement are as follows: 
  

							
	 	  	2009	  	2010
	 Name and Title
	  	Base Salary	  	Base
Salary
	 Hans R. Ganz
 President and Chief Executive Officer
	  	$	320,008	  	$	365,019
	 James P. Sheehy
 Executive Vice President—Secretary and Treasurer
	  	$	160,014	  	$	165,006
	 Melanie M. Yaptangco
 Executive Vice President—Lending
	  	$	160,014	  	$	165,006

 Description of 2009 Bonus Incentive
Plan  
 On January 13, 2009, the Company’s Compensation Committee approved a cash incentive bonus plan for 2009
(the “2009 Bonus Plan”) for all officers and employees of the Company and the Bank. The 2009 Bonus Plan is fully discretionary on the part of the Company’s Compensation Committee. The plan provides for a discretionary bonus pool of
funds which would not exceed 10% of after-tax net income with a minimum discretionary bonus pool amount of $150,000 in the aggregate. Bonuses will be paid under the 2009 Bonus Plan in early 2010. 
 The key performance indicators used to determine whether any bonuses will be paid under the 2009 Bonus Plan will be the same for all
administration employees. The amounts of the bonuses to be individually awarded under the 2009 Bonus Plan are fully discretionary, and may or may not be paid in whole or in part based on the Compensation Committee’s qualitative assessment of
individual contributions toward the Company’s success relative to its profitability, customer service, deposit growth, compliance, loan originations and portfolio growth, loan charge-off and delinquency ratios. Payout percentages will vary from
employee to employee. All named executive officers are eligible under the Plan. 
 For branch operations staff, a separate
branch sales incentive bonus plan has been created that is tied to individual deposit growth goals by branch, and is not dependent on the general income of the Company. 
 Director Fee Arrangements for 2009 
 Each director of First PacTrust
Bancorp, Inc., (the “Company”) also is a director of Pacific Trust Bank (the “Bank”). Directors are not paid a fee for service on the Company’s board. As of the March 13, 2009 shareholder record date for the 2009 annual
meeting, members of Pacific Trust Bank’s board of directors who are “independent directors” will receive an annual retainer fee of $5,000 in January of each calendar year. New directors who are elected or appointed to the board during
the year shall be paid a pro rata annual retainer equal to 1/12 of the $5,000 fee for each full or partial month remaining in that calendar year. 
 Independent directors shall be paid a fee of $2,000 for each Bank board meeting attended. In addition, the Chairman of the Board receives a 50% premium ($1,000) per Bank board meeting attended. Directors
are not paid additional fees for attendance at First PacTrust Bancorp, Inc. Board of Directors meetings. 
 Independent
directors are also paid fees for their service on various committees as follows: Executive Committee – $1,000 per meeting; Audit Committee – $600 per meeting; Compensation Committee – $600 per

 
meeting; Nominating Committee – $500 per meeting; Loan Committee – $2,000 per year; Technology Committee – $1,200 per year; and Facilities Committee – $2,000 per year. The
Committee Chairmen also received a 50% premium. 
 Attendance by telephone at Bank board meeting and committee meetings is
compensated at two-thirds the per meeting rate for directors attending in person. 
 Directors attending the Company/Bank’s
annual off-site planning session shall be paid $2,000 in addition to any Board of Director or Committee per meeting fees. 
 There are no deferred compensation arrangements with any non-employee director.First Amendment to Loan and Security Agreement

 Exhibit 10.1 
 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT 
 This
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of March 10, 2010, by and among Myriad Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Javelin Pharmaceuticals, Inc., a
Delaware corporation (the “Company”) and Innovative Drug Delivery Systems, Inc., a Delaware corporation (the “Subsidiary”). The Company and the Subsidiary are sometimes referred to individually as a
“Borrower” and collectively as the “Borrowers.” 
 RECITALS 

A. Parent and the Borrowers are parties to that certain Loan and Security Agreement dated as of December 18, 2009 (as may be so
amended, restated, or otherwise modified, the “Agreement”), pursuant to which Parent has, among other things, made funds available to the Borrowers in an aggregate principal amount of $6,000,000, which is evidenced by a Secured
Promissory Note dated as of December 18, 2009 in the stated principal amount of $6,000,000 (the “Original Note”). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings
respectively ascribed to them in the Agreement, as amended by this Amendment. 
 B. In connection with the Merger Agreement and
pursuant to the Agreement, Parent has made loans to the Borrowers in the aggregate principal amount of $6,000,000, upon the terms and subject to the conditions set forth in the Agreement. 
 C. The Borrowers have requested and Parent has agreed to provide additional loans to the Borrowers upon the terms and conditions set forth
in this Amendment. 
 D. The parties therefore desire to amend the Agreement and certain related documents in accordance with
the terms of this Amendment. 
 NOW, THEREFORE, the parties agree as follows: 
 1. AMENDMENTS TO AGREEMENT. 
 1.1 Section 1. 
 (a) Section 1 of the Agreement is hereby amended by amending and restating the following defined terms to read in their entirety as follows: 
 (i) “‘Maximum Loan Amount’ means $8,500,000; provided, however, that $500,000 of such funds may only be used by the Borrowers for Market Development Initiatives.” 

 (b) The following new definitions are hereby added to Section 1 as follows:

 (i) “‘Amendment’ means that certain First Amendment to Loan and Security Agreement dated as of
March 10, 2010, by and among Parent and the Borrowers.” 
 (ii) “‘Market Development
Initiatives’ means commercial initiatives and activities, as set forth on Schedule A hereto, related to Dyloject, the Company’s drug candidate for which a new drug application has been filed with and accepted for formal review by
the U.S. Food and Drug Administration. At the Company’s request, Parent will assist the Company in the design, planning, negotiation and implementation of the Market Development Initiatives.” 
 (iii) “‘Market Development Initiative Funds’ means the amount of any Loans (as defined below) used for Market
Development Initiatives in an amount not to exceed $500,000.” 
 (iv) “‘Note’ means
collectively, the Original Note and the New Note.” 
 1.2 Section 2. Section 2 of the Agreement is hereby
amended as follows: 
 (a) Section 2.1 of the Agreement is hereby amended and restated to read in its entirety as follows:

 “2.1 Bridge Loans. Subject to the terms and conditions hereinafter set forth, upon written request of the
Company given at least three (3) Business Days prior to the date on which the Borrowers seek a loan from Parent, which date shall be specified in such written request, Parent will make loans (each a “Loan” and collectively, the
“Loans”) to the Borrowers from time to time in an amount not to exceed $2,000,000 per month; provided, however, that (i) the aggregate original principal of all Loans to be made hereunder shall not exceed the Maximum Loan
Amount, (ii) $2,000,000 of the Maximum Loan Amount may not be loaned until after March 31, 2010, and (iii) and no Loans shall be made after April 30, 2010. Notwithstanding, anything contained herein to the contrary, Loans used
for Market Development Initiatives shall be available to Borrowers, subject to the terms and conditions set forth herein, immediately following the date of this Amendment until the earlier of (a) the date of termination of the Merger Agreement
and (b) April 30, 2010.” 
 (b) Section 2.2 of the Agreement is hereby amended and restated to read in its
entirety as follows: 
 “2.2 Note. The Loans shall be evidenced by the Original Note and that certain Secured
Promissory Note dated of even date herewith made by Borrowers and payable to the order of the Parent in the maximum, principal amount of $2,500,000, in the form attached hereto as Exhibit B (the “New Note”). Each Borrower
hereby irrevocably authorizes Parent to make or cause to be made, on a schedule attached to the Original Note or the New Note, as applicable, or on the books of Parent, at or following the time of making each loan and of receiving any payment of
principal balance of the Loans the designation of the amount of such Loan and payment. The amount so noted shall constitute prima facie evidence as to the amount owed by the Borrowers with respect to the principal amount of the Loans. Failure of
Parent to make any such notation shall not, however, affect any obligation of the Borrowers or any right of Parent hereunder or under the Note.” 
  

 2 

 (c) Section 2.4 of the Agreement is hereby amended and restated to read in its
entirety as follows: 
 “2.4 Payment of Principal and Interest. The principal amount of the Loans (other than the
Market Development Initiative Funds, including any interest thereon), all accrued interest thereon and all other amounts due under this Agreement and the other Note Documents shall be repaid in full on the first to occur of (a) the Closing
Date, (b) if the Merger Agreement is terminated pursuant to Section 10.01(h) or Section 10.01(i) thereof, two (2) Business Days following the Termination Date, provided, however, that if a Termination Fee and/or Parent Stipulated
Expenses shall be payable under Section 10.03(b) of the Merger Agreement within 90 days of termination of the Merger Agreement, then the two (2) Business Days referred to in this clause (b) shall be extended to ninety (90) days
following the Termination Date, (c) if the Merger Agreement is terminated pursuant to any other subsection of Section 10.01 thereof (other than Sections 10.01(h) or 10.01(i)), ninety (90) days following the Termination Date or
(d) acceleration as provided in Section 8.1 below. The principal amount of the Loans relating to the Market Development Market Development Initiative Funds, including any interest thereon, shall be repaid in full if the Merger Agreement is
terminated pursuant to Section 10.01(h)(iii), Section 10.01(h)(v) or Section 10.01(i) thereof and otherwise the Borrowers shall have no obligation to repay the Loans relating to the Market Development Initiative Funds or any interest
or other amounts owed thereon. The Borrowers may, at any time and from time to time, prepay the Loans in whole or in part without premium or penalty upon at least three (3) Business Days’ prior written notice to the Parent.”

 (d) Section 2.5 of the Agreement is hereby amended by adding the language “(other than any Loans relating to the
Market Development Initiative Funds and any interest thereon unless the Merger Agreement is terminated pursuant to Section 10.01(h)(iii), Section 10.01(h)(v) or Section 10.01(i) thereof)” after the word “Loans”.

 1.3 Exhibit C. The Form of Advance Certificate is hereby amended and restated to read in its entirety as set forth on
Exhibit C hereto. 
 2. LIMITATION. The amendments set forth in this Amendment shall be
limited precisely as written and shall not be deemed (a) to be a waiver or modification of any other term or condition of the Agreement or of any other instrument or agreement referred to therein or to prejudice any right or remedy which Parent
may now have or may have in the future under or in connection with the Agreement or any instrument or agreement referred to therein; or (b) to be a consent to any future amendment or modification or waiver to any instrument or agreement the
execution and delivery of which is consented to hereby, or to any waiver of any of the provisions thereof. Except as expressly amended hereby, the Agreement shall continue in full force and effect and is hereby ratified and confirmed. 
  

 3 

 3. EFFECTIVENESS. This Amendment shall become
effective upon the satisfaction of the following conditions precedent: 
 (a) Parent shall have received this Amendment, fully
executed by each Borrower; 
 (b) The Company shall have received this Amendment, fully executed by Parent; and 
 (c) The Borrowers shall have duly executed and delivered the New Note to Parent. 
 4. GENERAL PROVISIONS. 
 4.1 Counterparts. This Amendment may be executed and delivered (including by facsimile transmission) in two or more counterparts, and
by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. 
 4.2 Headings. The descriptive headings contained in this Amendment are included for convenience of reference only and shall not
affect in any way the meaning or interpretation of this Agreement. 
 [Remainder of Page Intentionally Left Blank] 
  

 4 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as a sealed
instrument as of the date first above written. 
  

									
	Witnessed by:	 		 		 		 	
		 		 	MYRIAD PHARMACEUTICALS, INC.
				
	 /s/ Andrew Gibbs
	 		 	By:	 	 /s/ Adrian N. Hobden

	Name:    Andrew Gibbs	 		 		 	Name:	 	Adrian N. Hobden
		 		 		 	Title:	 	President and Chief Executive Officer
					
	Witnessed by:	 		 		 		 	
		 		 	JAVELIN PHARMACEUTICALS, INC.
				
	 /s/ Frederick E. Pierce, II
	 		 	By:	 	 /s/ Martin J. Driscoll

	Name: Frederick E. Pierce, II	 		 		 	Name:	 	Martin J. Driscoll
		 		 		 	Title:	 	Chief Executive Officer
			
	Witnessed by:	 		 	INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
				
	 /s/ Frederick E. Pierce, II
	 		 	By:	 	 /s/ Martin J. Driscoll

	Name: Frederick E. Pierce, II	 		 		 	Name:	 	Martin J. Driscoll
		 		 		 	Title:	 	President & Chief Executive Officer

  

 5 

 EXHIBIT B 
 FORM OF SECURED PROMISSORY NOTE 
  

			
	$2,500,000	  	March 10, 2010

 FOR
VALUE RECEIVED, the undersigned Javelin Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Innovative Drug Delivery Systems, Inc., a Delaware corporation (the “Subsidiary”) (the Company and the
Subsidiary collectively, the “Borrowers”) hereby promise to pay to Myriad Pharmaceuticals, Inc. or its registered assigns (the “Holder”), in accordance with the provisions of the Agreement (as hereinafter defined),
the principal amount of $2,500,000 or such amount as is advanced from time to time by the Holder to the Borrowers under that certain Loan and Security Agreement, dated as of December 18, 2009, as amended on March 10, 2010 (as amended,
restated, extended, supplemented or otherwise modified in writing and in effect from time to time, the “Agreement”), among the Borrowers and the Holder. Capitalized terms used herein without definition shall have the respective
meanings provided therefor in the Agreement. 
 The Company promises to pay interest on the unpaid principal amount of each Loan
from the date of such Loan until such principal amount is paid in full, at such interest rate and at such times as provided in the Agreement. All payments of principal and interest shall be made to the Holder in Dollars in immediately available
funds. 
 This Secured Promissory Note is the New Note referred to in the Agreement, is entitled to the benefits thereof and may
be prepaid in whole or in part subject to the terms and conditions provided therein. This Note is secured by the Collateral. Upon the occurrence and continuation of one or more of the Events of Default specified in the Agreement, all amounts then
remaining unpaid on this Note shall become, or may be declared to be, immediately due and payable all as provided in the Agreement and subject to the terms thereof. 
 The Borrowers hereby waive diligence, presentment, protest and demand and notice of protest, demand, dishonor and non-payment of this Note. Each Borrower’s obligation hereunder is joint and several
as provided in the Agreement. 
 THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAW OF THE STATE OF
DELAWARE. 
  

							
	Witnessed:	 		 	JAVELIN PHARMACEUTICALS, INC.
				
	  
	 		 	By:	 	  

	Name:	 		 		 	Name: Martin J. Driscoll
		 		 		 	Title: Chief Executive Officer

  

 6 

							
	Witnessed:	 		 	INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
				
	  
	 		 	By:	 	  

	Name:	 		 		 	Name: Martin J. Driscoll
		 		 		 	Title:

  

 7 

 EXHIBIT C 
 FORM OF ADVANCE CERTIFICATE 
 Reference is hereby made to that certain Loan and
Security Agreement dated as of December 18, 2009, as amended on March 10, 2010, by and among Myriad Pharmaceuticals, Inc., Javelin Pharmaceuticals, Inc. and Innovative Drug Delivery Systems, Inc. (the “Loan Agreement”).
Capitalized terms used herein that are not otherwise defined herein shall have the meanings respectively ascribed to them in the Loan Agreement. Pursuant to the Loan Agreement, the undersigned hereby state as follows: 
 1. The Borrowers request that a Loan in the amount of $             be made to
the Borrowers on                     . The Borrowers certify that attached hereto as Exhibit A is a reasonably detailed summary of the
Borrowers’ intended use of the proceeds of the Loan. 
 2. The Borrowers hereby represent and warrant as of the date of
this Advance Certificate, which statements are and shall be correct and complete as of the date hereof and on the date the Loan is made after giving effect to such Loan: 
 (a) the Merger Agreement has not been terminated for any reason; 
 (b) all
statements, representations and warranties of the Borrowers made in the Loan Agreement are correct and complete in all material respects; provided, however, that such materiality qualifier shall not apply to any statements, representations and
warranties in the Loan Agreement that are already qualified by materiality; 
 (c) each Borrower is in full compliance with all
of the provisions of the Note Documents; 
 (d) the Company has not have received a Company Acquisition Proposal (that was not
solicited in violation of Section 8.03(a) of the Merger Agreement) following which Parent has requested that the Company Board reaffirm its approval and recommendation of the Merger and the Merger Agreement; and 
 (e) no Event of Default under Section 7.3 of the Loan Agreement has occurred. 
 Executed as a sealed instrument as of
                    . 
  

			
	 JAVELIN PHARMACEUTICALS, INC.

		
	By:	 	  

		 	    Name:
		 	    Title:
	
	 INNOVATIVE DRUG DELIVERY SYSTEMS, INC.

		
	By:	 	  

		 	    Name:
		 	    Title:

  

 8 

 SCHEDULE A 
 Market Development Initiatives 
 “Commercial Initiatives” shall include the
following commercial initiatives and activities: 
  

	 	•	 	 planning, preparation, sponsorship and implementation of continuing medical education programs; 

  

	 	•	 	 planning, preparation, sponsorship and implementation of an anesthesiology medical advisory board meeting and a pharmacy advisory board meeting; and

  

	 	•	 	 selection and engagement of qualified professional services or consultants to engage in activities related to: 

  

	 	•	 	 market research; 

  

	 	•	 	 sales force planning and training support; 

  

	 	•	 	 ad agency search and selection; 

  

	 	•	 	 national accounts support; 

  

	 	•	 	 supply chain and 3rd party logistics planning; 

  

	 	•	 	 manufacturing site audits; and 

  

	 	•	 	 medical affairs. 

  

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]